Modulatory effect of fenofibrate on endothelial production of neutrophil chemokines IL-8 and ENA-78

Cardiovascular Drugs and Therapy

Volumn 26, Issue 2, 2012, Pages 95-99

  Price, Elvin Tyrone ^a   Welder, Gregory James ^b   Zineh, Issam ^b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF FLORIDA HEALTH   (United States)

Author keywords

ENA 78; Endothelium; Fenofibrate; IL 8; Inflammation; Neutrophil

Indexed keywords

EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; FENOFIBRATE; INTERLEUKIN 1BETA; INTERLEUKIN 8; MESSENGER RNA;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL CULTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; PRIORITY JOURNAL; PROTEIN CONTENT; UMBILICAL VEIN ENDOTHELIAL CELL;

ANTI-INFLAMMATORY AGENTS; CELLS, CULTURED; CHEMOKINE CXCL5; CHEMOTAXIS, LEUKOCYTE; FENOFIBRATE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; IMMUNOLOGIC FACTORS; INTERLEUKIN-1BETA; INTERLEUKIN-8; NEUTROPHIL ACTIVATION; NEUTROPHILS; RNA, MESSENGER;

EID: 84862768520     PISSN: 09203206     EISSN: 15737241     Source Type: Journal    
DOI: 10.1007/s10557-011-6368-7     Document Type: Article

References (31)

1. Rosenson RS. Fenofibrate: treatment of hyperlipidemia and beyond. Expert Rev Cardiovasc Ther. 2008;6:1319-30.
2. FrickMH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987;317:1237-45. (Pubitemid 17147964)
3. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999;341:410-8. (Pubitemid 29362514)
4. Frick MH, Syvanne M, Nieminen MS, Kauma H, Majahalme S, Virtanen V, et al. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group. Circulation. 1997;96:2137-43.
5. Ericsson CG, Hamsten A, Nilsson J, Grip L, Svane B, de Faire U. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet. 1996;347:849-53. (Pubitemid 26099535)
6. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation. 2000; 102(1): 21-7.
7. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366:1849-61.
8. Ye HJ, Zhao SP. Anti-atherogenic properties of fibrates may be largely due to their anti-inflammatory effects. Med Hypotheses. 2006;66:495-500.
9. Horne BD, Anderson JL, John JM, Weaver A, Bair TL, Jensen KR, et al. Which white blood cell subtypes predict increased cardiovascular risk? J Am Coll Cardiol. 2005;45:1638-43. (Pubitemid 40704499)
10. Damas JK, Gullestad L, Ueland T, Solum NO, Simonsen S, Froland SS, et al. CXC-chemokines, a new group of cytokines in congestive heart failure-possible role of platelets and monocytes. Cardiovasc Res. 2000;45:428-36. (Pubitemid 30069508)
11. Hamid C, Norgate K, D'Cruz DP, Khamashta MA, Arno M, Pearson JD, et al. Anti-beta2GPI-antibody-induced endothelial cell gene expression profiling reveals induction of novel pro-inflammatory genes potentially involved in primary antiphospholipid syndrome. Ann Rheum Dis. 2007;66:1000-7. (Pubitemid 47122310)
12. Holm T, Damas JK, Holven K, Nordoy I, Brosstad FR, Ueland T, et al. CXC-chemokines in coronary artery disease: possible pathogenic role of interactions between oxidized low-density lipoprotein, platelets and peripheral blood mononuclear cells. J Thromb Haemost. 2003;1:257-62.
13. Middleton RK, Lloyd GM, Bown MJ, Cooper NJ, London NJ, Sayers RD. The pro-inflammatory and chemotactic cytokine microenvironment of the abdominal aortic aneurysm wall: a protein array study. J Vasc Surg. 2007;45:574-80. (Pubitemid 46281517)
14. Zaremba J, Skrobanski P, Losy J. The level of chemokine CXCL5 in the cerebrospinal fluid is increased during the first 24 hours of ischaemic stroke and correlates with the size of early brain damage. Folia Morphol (Warsz). 2006;65:1-5.
15. Zineh I, Beitelshees AL, Welder GJ, Hou W, Chegini N, Wu J, et al. Epithelial neutrophil-activating peptide (ENA-78), acute coronary syndrome prognosis, and modulatory effect of statins. PLoS One. 2008;3:e3117.
16. Zineh I, Luo X, Welder GJ, Debella AE, Wessel TR, Arant CB, et al. Modulatory effects of atorvastatin on endothelial cell-derived chemokines, cytokines, and angiogenic factors. Pharmacotherapy. 2006;26:333-40. (Pubitemid 43334672)
17. Lee H, Shi W, Tontonoz P, Wang S, Subbanagounder G, Hedrick CC, et al. Role for peroxisome proliferator-activated receptor alpha in oxidized phospholipid-induced synthesis of monocyte chemotactic protein-1 and interleukin-8 by endothelial cells. Circ Res. 2000;87:516-21.
18. Ryoo S, Won M, Kim DU, Kim L, Han G, Park SK, et al. PPARalpha activation abolishes LDL-stimulated IL-8 production via AP-1 deactivation in human aortic smooth muscle cells. Biochem Biophys Res Commun. 2004;318:329-34. (Pubitemid 38553784)
19. Shu H, Wong B, Zhou G, Li Y, Berger J, Woods JW, et al. Activation of PPARalpha or gamma reduces secretion of matrix metalloproteinase 9 but not interleukin 8 from human monocytic THP-1 cells. Biochem Biophys Res Commun. 2000;267:345-9. (Pubitemid 30072554)
20. Polenova NV, Vaulin NA, Masenko VP, Iavelov IS, Gratsianskii NA. Rosuvastatin and fenofibrate in patients with diabetes and low high density lipoprotein cholesterol: comparison of changes of lipid levels and some markers of inflammation. Kardiologiia. 2009;49:9-14.
21. Rosenson RS. Effect of fenofibrate on adiponectin and inflammatory biomarkers in metabolic syndrome patients. Obesity (Silver Spring). 2009;17:504-9.
22. Rosenson RS, Huskin AL, Wolff DA, Helenowski IB, Rademaker AW. Fenofibrate reduces fasting and postprandial inflammatory responses among hypertriglyceridemia patients with the metabolic syndrome. Atherosclerosis. 2008;198:381-8.
23. Rosenson RS, Wolff DA, Huskin AL, Helenowski IB, Rademaker AW. Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory response in subjects with hypertriglyceridemia and the metabolic syndrome. Diabetes Care. 2007;30:1945-51. (Pubitemid 47219398)
24. Shen J, Arnett DK, Parnell LD, Peacock JM, Lai CQ, Hixson JE, et al. Association of common C-reactive protein (CRP) gene polymorphisms with baseline plasma CRP levels and fenofibrate response: the GOLDN study. Diabetes Care. 2008;31:910-5.
25. Toyoda T, Kamei Y, Kato H, Sugita S, Takeya M, Suganami T, et al. Effect of peroxisome proliferator-activated receptor-alpha ligands in the interaction between adipocytes and macrophages in obese adipose tissue. Obesity (Silver Spring). 2008;16:1199-207. (Pubitemid 351771340)
26. Wu TJ, Ou HY, Chou CW, Hsiao SH, Lin CY, Kao PC. Decrease in inflammatory cardiovascular risk markers in hyperlipidemic diabetic patients treated with fenofibrate. Ann Clin Lab Sci. 2007;37:158-66. Spring. (Pubitemid 46717194)
27. Bergman AJ, Murphy G, Burke J, Zhao JJ, Valesky R, Liu L, et al. Simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humans. J Clin Pharmacol. 2004;44:1054-62. (Pubitemid 39096820)
28. Goya K, Sumitani S, Xu X, Kitamura T, Yamamoto H, Kurebayashi S, et al. Peroxisome proliferator-activated receptor alpha agonists increase nitric oxide synthase expression in vascular endothelial cells. Arterioscler Thromb Vasc Biol. 2004;24:658-63. (Pubitemid 38451600)
29. Thomas J, Bramlett KS, Montrose C, Foxworthy P, Eacho PI, McCann D, et al. A chemical switch regulates fibrate specificity for peroxisome proliferator-activated receptor alpha (PPARalpha) versus liver X receptor. J Biol Chem. 2003;278:2403-10. (Pubitemid 36801314)
30. Chang MS, McNinch J, Basu R, Simonet S. Cloning and characterization of the human neutrophil-activating peptide (ENA-78) gene. J Biol Chem. 1994;269:25277-82. (Pubitemid 24336204)
31. Staels B, Koenig W, Habib A, Merval R, Lebret M, Torra IP, et al. Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature. 1998;393:790-3. (Pubitemid 28299490)